Program Planners – Editor and Associate Editors and Guest Editors
Mark H. Rapaport, M.D., Editor of FOCUS, and Chairman and Chief of Psychiatric Services, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Ga. No financial relationships with commercial interests.
Dorothy Stubbe, M.D., Editor Communications Commentary, Associate Professor and Program Director, Yale University School of Medicine Child Study Center, New Haven, CT.- No financial relationships with commercial interests.
Laura Dunn, M.D., Co-Editor Ethics Column; Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA; Dr. Dunn reports: Consultant: Otsuka America Pharmaceutical Inc.
Ian A. Cook, M.D., D.F.A.P.A. Guest Editor, Section Editor and Author Patient Management: is Chief Translational Innovation Officer for the Semel Institute for Neuroscience and Human Behavior, and is a Professor with the Department of Psychiatry and Biobehavioral Sciences of the David Geffen School of Medicine, and the Department of Bioengineering of the Henry Samueli School of Engineering and Applied Science at the University of California, Los Angeles. He is also with the Veterans Affairs Greater Los Angeles Healthcare System. Dr. Cook reports that his active biomedical device patents are assigned to the University of California. In the last year, he has advised Arctica Health, Cerêve, and NeuroDetect, and UCLA has received research grant funding from NeoSync, Inc., for his work. He has been granted stock options in NeuroSigma, the licensee of some of his inventions, and he currently is on-leave as its chief medical officer and senior vice president.
Boadie Dunlop, M.D. Section Editor Applied Armamentarium, Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia. Grant/Research: Axome, Assurex, Acadia, Janssen, NIMH, Takeda
FOCUS Author Affiliation and Disclosure Information
Whole-Body Heating: An Emerging Therapeutic Approach to Treatment of Major Depressive Disorder
Christopher Lowry, Ph.D., Michael Flux, M.S., Charles Raison, M.D.
Dr. Lowry is with the Department of Integrative Physiology and Center for Neuroscience, University of Colorado, Boulder. Mr. Flux is with the Department of Psychology and Neuroscience, University of Colorado, Boulder. Dr. Raison is with the School of Human Ecology, University of Wisconsin. During the preparation of this article, Dr. Lowry was supported by a grant from the National Institute of Mental Health (grant number 1R21MH116263); a grant from the U.S. Department of the Navy, Office of Naval Research Multidisciplinary University Research Initiative (MURI; grant number N00014-15-1-2809); a grant from the Department of Veterans Affairs Office of Research and Development (VA-ORD) RR&D Small Projects in Rehabilitation Research (SPiRE [I21]; grant number 1 I21 RX002232-01); a grant from the Colorado Clinical & Translational Sciences Institute (CCTSI) Center for Neuroscience (grant number CNSTT- 15-145); a grant from the Colorado Department of Public Health and Environment (CDPHE; grant number DCEED-3510); and a grant from the Alfred P. Sloan Foundation (grant number G-2016-7077). Dr. Lowry serves on the Scientific Advisory Board of Immodulon Therapeutics, Ltd. Dr. Raison is director of Clinical and Translational Research for Usona Institute Alkermes and Novartis.Mr. Flux reports no financial relationships with commercial interests.
Digital Technologies in Psychiatry: Present and Future
Mathew E. Hirschtritt, M.D., M.P.H., and Thomas R. Insel, M.D.
Dr. Hirschtritt is with the Weill Institute for Neurosciences and Department of Psychiatry, University of California, San Francisco. Dr. Insel is with Mindstrong Health, Palo Alto, CA
This work was funded in part by grant 5R25MH060482-17 from the National Institute of Mental Health (NIMH) to Dr. Hirschtritt. NIMH funding had no involvement in the conception, drafting, review, or approval of the manuscript. Dr. Hirschtritt serves as a consultant to Carbon Health. Dr. Insel is an employee of Mindstrong Health and has equity interest in Alphabet, Apple, and Mindstrong Health. He serves on the boards of Mindstrong Health, Inscopix, Compass Pathways, and 7 Cups.
Ethical Issues in Emerging Treatments for Neuropsychiatric Disorders
Paul P. Christopher, M.D. Dr. Christopher is with the Department of Psychiatry and Human Behavior, Warren Alpert Medical School, Brown University, Providence, RI. Dr. Christopher reports no financial relationships with commercial interests.
Experimental Therapies for Treatment-Resistant Depression
Manish K. Jha, M.D., Madhukar jjH. Trivedi, M.D., Center for Depression Research and Clinical Care, UT Southwestern Medical Center, Dallas, TX.
Dr. Jha, Grant Research: Acadia Pharmaceuticals and Janssen Research
Dr. Trivedi: Consultant:Alkeremes Inc., Akili Interactive, Navitor, Otsuka America Pharmaceutical Inc., Speaker's Bureau: Dartmouth College, Global Medical Education, University of Illinois Chicago, University of Ottawa, University of Texas Health Science Center at San Antonio. Grant/Research: (NIMH), (NIDA), National Center for Advancing Translational Sciences, Cancer Prevention and Research Institute of Texas, Patient-Centered Outcomes Research Institute (PCORI). Author Agreement: Janssen Asia Pacific, Oxford University Press;
Clinical Virtual Reality: Emerging Opportunities for Psychiatry
Albert “Skip” Rizzo, Ph.D., Director of Medical Virtual Reality Research, University of Southern California Institute for Creative Technologies. Sebastian Thomas Koenig, Ph.D., Director, Human Interface Technology Engineer Katana Simulations Pty Ltd, Adelaide, Australia. Thomas Talbot, M.D., Senior Research Scientist University of Southern California Institute for Creative Technologies
Dr. Rizzo reports no financial conflict relationships.
Dr. Koenig reports 100% ownership interest in Katana Simulations Pty Ltd, an Australian technology company developing clinical and educational virtual reality software.
Dr. Talbot, Consultant: Talbotics LLC - Consultant for National Board of Medical Examiners, U. Washington, U. Illinois Jump Simulation, Applied Research Associates, Charles River Analytics. Grant/Research: Multiple Grants from US Department of Defense for medical simulation. Other: Medical Mechanica LLC - virtual standardized patient technology licensing & development (owner)
Ketamine- A Review for Clinicians
Gerard Sanacora, M.D. Rachael Katz, M.D., Yale Department of Psychiatry Yale Interventional Psychiatry Service, Yale Psychiatric Hospital
Dr. Sanacora reports: Stock: Biohaven Pharmaceutical Company. Consultant: Allergan, Alkermes, Axsome Therapeutics, Biohaven Pharmaceuticals, Intra-Cellular Therapies, Janssen, Navitor Pharmaceuticals, Noven Pharmaceuticals, Sage Pharmaceuticals, Sofinnova, and Vistagen Therapeutics. Grant/Research: Merck and Janssen. Co-inventor on a patent, “Glutamate agents in the treatment of mental disorders”: Patent number: 8778979. Dr. Katz reports no relevant financial conflicts with commercial entities.
American Psychiatric Association staff involved in planning report no financial relationships with commercial interests:
Tristan Gorrindo M.D., Director, Division of Education, American Psychiatric Association
Kristen Moeller, Director of CME, Associate Director of FOCUS, American Psychiatric Association
FOCUS Editorial Board disclosure is published on the editorial board page of each issue.